Andro Targeted By FDA In Coordination With Capitol Hill Action
This article was originally published in The Tan Sheet
Executive Summary
FDA is aiming to remove androstenedione supplements from the market by classifying the substance as a new dietary ingredient that has not been the subject of a safety notification to the agency, as required by the Dietary Supplement Health & Education Act
You may also be interested in...
DMAA Warnings Shed Light On FDA NDI Enforcement
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
DMAA Warnings Shed Light On FDA NDI Enforcement
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
FDA Warning Draws Solid Line Between Steroid Products And Supplements
FDA's enforcement approach toward a firm warned about marketing synthetic steroids as dietary supplements represents a more watertight legal strategy than the agency has used in similar scenarios